Overview

A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes

Status:
ENROLLING_BY_INVITATION

Trial end date:
2026-11-13

Target enrollment:

Participant gender:

Summary

This study is a multicenter, randomized, double-blind, parallel-controlled, phase III clinical trial to evaluate efficacy and safety of the triple combination therapy of prusogliptin, dapagliflozin and metformin in subjects with type 2 diabetes who have inadequate glycemic control on metformin alone.

Phase:

PHASE3

Details

Lead Sponsor:

CSPC Ouyi Pharmaceutical Co., Ltd.

Treatments:

dapagliflozin